Click here to view the presentation slides. Download (PDF)
A better understanding of the molecular pathogenesis of basal cell carcinoma (BCC) has led to the discovery of novel targeted agents for its management. As a result, there is a critical need to relay this information to all members of the multidisciplinary cancer care team involved in treating patients with BCC.
Understanding the Evolving Strategies to Improve Patient Outcomes in Basal Cell Carcinoma will allow clinicians to explore all the recent advances in the management of BCC, and provide guidance on evidence-based and clinically relevant quality measures to improve the quality of care that patients receive.
This program is intended for dermatology and oncology specialists, including dermatologists, dermatology surgeons, oncologists, ENT and plastic surgeons, and other clinicians involved in the care of patients with BCC.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Assess multimodality treatment options for patients with advanced BCC
- Evaluate the safety and efficacy data of novel agents for the management of advanced BCC
- Review the current clinical recommendations regarding the management of advanced BCC
Karl Lewis, MD
Associate Professor of Medicine
Division of Medical Oncology
Melanoma Research Clinics
University of Colorado Denver
Karl Lewis, MD: Biography coming soon.
Aleksandar Sekulic, MD, PhD
Assistant Professor of Dermatology
Mayo Clinic in Arizona
Aleksandar Sekulic, MD, PhD received his medical doctorate from the University of Zagreb School of Medicine in Croatia, then attended Mayo Graduate School, where he completed the PhD in immunology. He further trained at Mayo Graduate School of Medicine where he completed a residency in dermatology.
Dr. Sekulic's clinical practice focuses on cutaneous oncology, including malignant melanoma and other pigmented lesions, epidermal neoplasms, and cutaneous T-cell lymphoma. His research is centered on developing translational approaches for the study of genomics in skin diseases, identifying the genetics and molecular mechanisms of malignant melanoma, discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation in human skin disease.
Dr. Sekulic is a recipient of the Excellence in Teaching Recognition Award at Mayo Medical School. He also received the 2012 Gerstner Family Foundation Career Development Award in Individualized Medicine. He has given international, national, and regional presentations and has co-authored several articles, book chapters, and abstracts which have been published in numerous peer-reviewed journals. His research has been funded by the National Cancer Institute and other organizations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email email@example.com.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided upon completion of the evaluation.
There is no fee associated with this program.
Event staff will be glad to assist you with any special needs. Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly PROVIDED By
|Jointly provided by Potomac Center for Medical Education and Rockpointe Oncology
This educational activity has been supported by an educational grant from Novartis Pharmaceuticals Corporation.
By clicking the Registration Button below you are agreeing that you have read and understood the CME/CE Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.